Literature DB >> 35947248

In silico study of tacrine and acetylcholine binding profile with human acetylcholinesterase: docking and electronic structure.

Letícia A Nascimento1, Érica C M Nascimento1, João B L Martins2.   

Abstract

Alzheimer disease (AD) is a neurodegenerative process, one of the most common and incident dementia in the population over 60 years. AD manifests the presence of complex biochemical processes involved in neuronal degeneration, such as the formation of senile plaques containing amyloid-β peptides, the development of intracellular neurofibrillary tangles, and the suppression of the acetylcholine neurotransmitter. In this way, we performed a set of theoretical tests of tacrine ligand and acetylcholine neurotransmitter against the human acetylcholinesterase enzyme. Molecular docking was used to understand the most important interactions of these molecules with the enzyme. Computational chemistry calculation was carried out using MP2, DFT, and semi-empirical methods, starting from molecular docking structures. We have also performed studies regarding the non-covalent interactions, electron localization function, molecular electrostatic potential and explicit water molecule influence. For Trp86 residue, we show two main interactions in accordance to the results of the literature for TcAChE. First, intermolecular interactions of the cation-π and sigma-π type were found. Second, close stacking interactions were stablished between THA+ and Trp86 residue on one side and with Tyr337 residue on the other side.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Acetylcholine; Acetylcholinesterase; Alzheimer; Docking; ELF; NCI; s disease

Mesh:

Substances:

Year:  2022        PMID: 35947248     DOI: 10.1007/s00894-022-05252-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   2.172


  38 in total

1.  Acetylcholine Receptor Stimulation for Cognitive Enhancement: Better the Devil You Know?

Authors:  Mark G Baxter; Johanna L Crimins
Journal:  Neuron       Date:  2018-06-27       Impact factor: 17.173

2.  M1 muscarinic acetylcholine receptor-mediated inhibition of GABA release from striatal medium spiny neurons onto cholinergic interneurons.

Authors:  Etsuko Suzuki; Toshihiko Momiyama
Journal:  Eur J Neurosci       Date:  2020-12-20       Impact factor: 3.386

3.  Deciphering the AChE-binding mechanism with multifunctional tricyclic coumarin anti-Alzheimer's agents using biophysical and bioinformatics approaches and evaluation of their modulating effect on Amyloidogenic peptide assembly.

Authors:  Jeelan Basha Shaik; Yelamanda Rao Kandrakonda; Monika Kallubai; Navya Naidu Gajula; Shreya Dubey; Bindu Madhava Reddy Aramati; Rajagopal Subramanyam; Gangaiah Damu Amooru
Journal:  Int J Biol Macromol       Date:  2021-11-02       Impact factor: 6.953

Review 4.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

5.  Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus.

Authors:  Takako Ohno-Shosaku; Minoru Matsui; Yuko Fukudome; Jumpei Shosaku; Hiroshi Tsubokawa; Makoto M Taketo; Toshiya Manabe; Masanobu Kano
Journal:  Eur J Neurosci       Date:  2003-07       Impact factor: 3.386

6.  Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.

Authors:  Michela Rosini; Elena Simoni; Manuela Bartolini; Andrea Cavalli; Luisa Ceccarini; Nicoleta Pascu; David W McClymont; Andrea Tarozzi; Maria L Bolognesi; Anna Minarini; Vincenzo Tumiatti; Vincenza Andrisano; Ian R Mellor; Carlo Melchiorre
Journal:  J Med Chem       Date:  2008-07-08       Impact factor: 7.446

Review 7.  Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.

Authors:  Jiyeon Han; Zhi Du; Mi Hee Lim
Journal:  Acc Chem Res       Date:  2021-10-04       Impact factor: 22.384

Review 8.  AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.

Authors:  Yu Wang; Hao Wang; Hong-zhuan Chen
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 9.  Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy.

Authors:  Thaiane Coelho Dos Santos; Thaís Mota Gomes; Bruno Araújo Serra Pinto; Adriana Leandro Camara; Antonio Marcus de Andrade Paes
Journal:  Front Pharmacol       Date:  2018-10-18       Impact factor: 5.988

10.  Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors.

Authors:  Navneet Kumar; Anuj Gahlawat; Rajaram Naresh Kumar; Yash Pal Singh; Gyan Modi; Prabha Garg
Journal:  J Biomol Struct Dyn       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.